Swiss National Bank increased its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 4.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,300 shares of the medical instruments supplier’s stock after purchasing an additional 1,300 shares during the period. Swiss National Bank owned approximately 0.16% of LeMaitre Vascular worth $1,161,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Principal Financial Group Inc. boosted its holdings in shares of LeMaitre Vascular by 297.4% in the 4th quarter. Principal Financial Group Inc. now owns 533,334 shares of the medical instruments supplier’s stock worth $19,174,000 after purchasing an additional 399,120 shares during the period. Russell Investments Group Ltd. lifted its position in LeMaitre Vascular by 92.3% in the third quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after buying an additional 173,214 shares during the last quarter. Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 38.7% during the third quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after buying an additional 149,642 shares during the period. Cadence Capital Management LLC purchased a new position in LeMaitre Vascular during the fourth quarter worth $2,036,000. Finally, Wedge Capital Management L L P NC boosted its stake in LeMaitre Vascular by 192.0% during the fourth quarter. Wedge Capital Management L L P NC now owns 70,736 shares of the medical instruments supplier’s stock worth $2,543,000 after buying an additional 46,512 shares during the period. Institutional investors own 86.60% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. Roth Capital reissued a “neutral” rating on shares of LeMaitre Vascular in a research note on Monday, February 24th. BidaskClub upgraded shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a report on Friday, February 21st. Zacks Investment Research lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Barrington Research reissued a “buy” rating and issued a $38.00 price objective on shares of LeMaitre Vascular in a research note on Friday, February 7th. Finally, ValuEngine upgraded LeMaitre Vascular from a “sell” rating to a “hold” rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $37.75.
In other news, CFO Joseph P. Pellegrino, Jr. sold 710 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $36.07, for a total transaction of $25,609.70. Following the transaction, the chief financial officer now directly owns 11,021 shares in the company, valued at $397,527.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 6,068 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $36.17, for a total transaction of $219,479.56. Following the transaction, the chief financial officer now directly owns 41,491 shares in the company, valued at $1,500,729.47. The disclosure for this sale can be found here. Insiders sold a total of 66,814 shares of company stock valued at $2,436,247 over the last quarter. Company insiders own 19.60% of the company’s stock.
Shares of NASDAQ LMAT traded down $1.05 during mid-day trading on Monday, reaching $26.95. The company had a trading volume of 6,614 shares, compared to its average volume of 178,585. The business’s 50-day moving average is $32.46 and its 200-day moving average is $33.90. The stock has a market cap of $576.55 million, a price-to-earnings ratio of 30.68, a price-to-earnings-growth ratio of 3.70 and a beta of 1.47. LeMaitre Vascular Inc has a 52 week low of $25.39 and a 52 week high of $38.64.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $0.23 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.23. The company had revenue of $30.20 million during the quarter, compared to analyst estimates of $30.44 million. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the business posted $0.30 EPS. As a group, sell-side analysts predict that LeMaitre Vascular Inc will post 0.93 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, March 3rd will be given a dividend of $0.095 per share. The ex-dividend date is Monday, March 2nd. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.09. This represents a $0.38 dividend on an annualized basis and a yield of 1.41%. LeMaitre Vascular’s payout ratio is 43.18%.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
See Also: What is the Current Ratio?
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.